A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (multivalent conjugate) and Prevenar 13 in Streptococcus Pneumoniae Infection, sponsored by Fosun Adgenvax Biopharmaceutical Co.,Ltd.. Active, not recruiting at 5 sites in China. Open to participants aged 6 Weeks to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Fosun Adgenvax Biopharmaceutical Co.,Ltd. (part of Fosun Pharma) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Pneumococcal Infections with a site in China — 6 open to participants now, 9 under way, 4 of them phase 3. Pneumococcal Infections · China.
Among the 36 studies in Pneumococcal Infections with a site in China, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 17th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →6 of the 36 studies in Pneumococcal Infections with a site in China are open now. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 6 wk+ · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–5 yrs · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–23 mo · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 6 wk–5 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 6 Weeks to 3 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 5 · Phase 3 9 · Phase 4 6
First in 2007; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 480 across the 33 interventional studies, 3,641 across the 3 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Fosun Adgenvax Biopharmaceutical Co.,Ltd., one of the names counted as Fosun Pharma. Under that name alone:
This is the only study on the registry with Fosun Adgenvax Biopharmaceutical Co.,Ltd. as lead sponsor.
Fosun Pharma has 1 study filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumococcal Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600983CanSino Biologics Inc.Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | 2026-11-24 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Pneumococcal Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months. The main objectives of the study include: 1. To evaluate the immunogenicity of the trial vaccine in infants aged 2 months (at least 6 weeks) following the corresponding immunization schedule compared to the control vaccine; 2. To evaluate the immunogenicity of the trial vaccine in infants aged 3 months following the corresponding immunization schedule compared to the 2-month group; 3. To evaluate the safety of the trial vaccine in infants aged 2 months (at least 6 weeks) and 3 months following the corresponding immunization schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary immunization phase:
Booster immunization phase:
Exclusion Criteria:
Primary immunization phase:
Booster immunization phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccination of 4 doses of experimental vaccine(0,2,4,1 booster dose)
Biological: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
Vaccination of 4 doses of control vaccine(0,2,4,1 booster dose)
Biological: Prevenar 13
Vaccination of 4 doses of experimental vaccine(0,1,2,1 booster dose)
Biological: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)
the 2-month-old experimental group and the 3-month-old group received the experimental vaccine
the 2-month-old control group received the active control vaccine
seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies
Immunogenicity
Time frame: 30 days after primary immunization
13 vaccine serotype-specific pneumococcal IgG antibodies GMC
Immunogenicity
Time frame: 30 days after primary immunization
incidence of adverse events (AE)
Safety
Time frame: 30 minutes/0~7 days/0~30 days after each dose of vaccination
incidence of all serious adverse events (SAEs)
Safety
Time frame: from the first dose to 6 months after primary immunization
incidence of all serious adverse events (SAEs)
Safety
Time frame: from the first dose of vaccination to 12 months after the booster immunization
percentage of subjects with 13 vaccine serotype-specific pneumococcal IgG antibody concentrations ≥1.0 μg/ml
Primary stage
Time frame: 30 days after primary immunization
the positivity rate of pneumococcal OPA antibodies for 13 vaccine serotypes
Primary stage
Time frame: 30 days after primary immunization
the GMT of pneumococcal OPA antibodies for 13 vaccine serotypes
Primary stage
Time frame: 30 days after primary immunization
the seroconversion rate of pneumococcal OPA antibodies for 13 vaccine serotypes
Primary stage
Time frame: 30 days after primary immunization
seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies
Booster stage
Time frame: 30 days after booster immunization
percentage of subjects with 13 vaccine serotype-specific pneumococcal IgG antibody concentrations ≥ 1.0 μg/mL
Booster stage
Time frame: 30 days after booster immunization
GMC of 13 vaccine serotype-specific pneumococcal IgG antibodies
Booster stage
Time frame: 30 days after booster immunization
the positivity rate of pneumococcal OPA antibodies for 13 vaccine serotypes
Booster stage
Time frame: 30 days after booster immunization
the GMT of pneumococcal OPA antibodies for 13 vaccine serotypes
Booster stage
Time frame: 30 days after booster immunization
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Jun 2025, 31 months after the start.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 31 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.